Carcinotech
Reinventing Cancer Research
An innovative MedTech Company
Carcinotech is a MedTech company with expertise in manufacturing 3D printed living tumours using patient-derived biopsies, primary cells, immune cells and cancer stem cells. Carcinotech’s advanced models provide a platform for rapid, ethical, and accurate drug screening, pre-clinical and personalised medicine testing.
Working with global partners, leading pharma companies, surgeons, pathologists, clinicians, and industry leaders, the goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market.
Access to Carcinotech’s robotic and automated manufacturing allows for accelerated production, with models offering high-throughput capabilities.
Innovation in Cancer Research
The WHO estimates the total number of cancer cases will reach 22 million by 2030. Currently, 90% of clinical trials fail to reach the market highlighting a huge challenge within the industry that requires an innovative solution. Outdated, inaccurate, and expensive techniques used in the manufacturing of drugs mean that current drug pipelines can take 10-15 years to deliver new cancer treatments to market. Identifying these issues, Chief Executive, Ishani Malhotra wanted to develop a technology that would directly address this problem so cancer drugs can get to market faster making innovative treatments available to all. Having identified a niche within the 3D bioprinting sector Ishani founded Carcinotech to address these issues, developing Carcinotech’s advanced capabilities in 3D printing micro tumours to aid pharma companies, surgeons, pathologists, and clinicians to accelerate drug screening and enable the delivery of more effective cancer treatments to market.
Carcinotech's vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to each individual suffering from cancer to better their chance of treatment and survival. Working with a wide range of clients, Ishani Malhotra, who was recently recognised by Scottish Business Insiders 35 under 35 Rising stars of 2022, aims to disrupt the oncology drug market, offering personalised medicine and assay services to clients across 6 cancers (Brain, Breast, Lung, Ovarian, Colorectal and Rare cancers) with continuous development into further cancer types. Carcinotech’s technology holds the potential to revolutionise cancer research, offering surgeons and oncologists the opportunity to test treatment options, drug responses and create treatment plans for each patient.
How Carcinotech Works